Modified Fibonacci Design is a dose escalation method in clinical trial design that uses a modified sequence of dose increments—typically starting with larger ratios that asymptotically approach a constant increase—to balance between rapid initial escalation and controlled dose expansion, distinguishing it from fixed-ratio or standard Fibonacci-based escalation schemes.
37
Publications
2.4K
Citations
322
Authors
90
Institutions
Publications per year
2017–2026
4
Parents
Publications
37
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Daniel R. Budman, Neal J. Meropol, Bruno Reigner et al. · Journal of Clinical Oncology · 1998 · 259 citations
Medicine, Oncology, Pharmacology +17
Phase I Clinical Trial Design in Cancer Drug Development
Elizabeth A. Eisenhauer, Peter J. O’Dwyer, Michaele C. Christian et al. · Journal of Clinical Oncology · 2000 · 240 citations
Medicine, Oncology, Pharmacology +14
Potential roles for preclinical pharmacology in phase I clinical trials.
Jerry M. Collins, Daniel S. Zaharko, Robert L. Dedrick et al. · PubMed · 1986 · 213 citations
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz, Andrew Brenner, Eric T. Wong et al. · Clinical Cancer Research · 2013 · 181 citations
Medicine, Oncology, Pharmacology +17
1–5 of 37
Authors
322
- JSJohn Sarantopoulos
The University of Texas at San Antonio Health Science Center, United States
3 publications · 234 citations
3
h-index
- EH
2
h-index
- DP
2
h-index
- MB
2
h-index
- KPKyriakos P. Papadopoulos
South Texas Accelerated Research Therapeutics, United States
2 publications · 57 citations
2
h-index
1–5 of 322
Institutions
90
South Texas Accelerated Research Therapeutics
San Antonio, United States
3 h-index
3 publications
107 citations
Dana-Farber Cancer Institute
Boston, United States
3 h-index
21 publications
3.4K citations
Massachusetts General Hospital
Boston, United States
3 h-index
4 publications
162 citations
Memorial Sloan Kettering Cancer Center
New York, United States
3 h-index
46 publications
5.4K citations
Mersana Therapeutics (United States)
Cambridge, United States
2 h-index
6 publications
204 citations
Tennessee Oncology
Nashville, United States
2 h-index
3 publications
118 citations
Sarah Cannon
Nashville, United States
2 h-index
7 publications
222 citations
The University of Texas MD Anderson Cancer Center
Houston, United States
2 h-index
2 publications
64 citations
1–8 of 90
Venues
- Journal of Clinical Oncology
13 publications · 1K citations
12
h-index
- PubMed
Repository · 7 publications · 617 citations
7
h-index
- Clinical Cancer Research
3 publications · 280 citations
3
h-index
- Cancer
2 publications · 40 citations
2
h-index
- British Journal of Cancer
BJC · 2 publications · 126 citations
2
h-index
1–5